Our Future is Biotech : A Plain English Guide to How a Tech Revolution is Changing Our Lives and Our Health for the Better - Andrew Craig

Our Future is Biotech

A Plain English Guide to How a Tech Revolution is Changing Our Lives and Our Health for the Better

By: Andrew Craig

eBook | 29 August 2024

Sorry, we are not able to source the ebook you are looking for right now.

We did a search for other ebooks with a similar title, however there were no matches. You can try selecting from a similar category, click on the author's name, or use the search box above to find your ebook.

The Apples, Amazons and Googles of the next few decades will be biotech companies. The tech companies of the last few years have changed how we do things but the businesses driving the biotech revolution are about making life better. These companies will solve many of our most intractable problems: cancer, dementia, diabetes, elderly care, mental health challenges, even power generation and agricultural production. Biotech will mean that we can live far better, safer, healthier, wealthier, happier, and longer lives.

Very few people in the general population have any idea of the phenomenal progress being made in these areas. There are already "miracle cures" for several diseases with far more to come. Exponential progress will drive the price of such things down far enough to make them widely available globally. This goes a long way beyond just "healthcare". These technologies could be key to dealing with climate change and the destruction of the natural world.

This is a landmark and important book by a biotech investment expert who has been working in the industry for the past 6.5 years and knows how biotech does and doesn't work, as well as having a fair few interesting stories about working with some of the leading players / companies in the space. To add a current spin to this, his biggest client, Oxford Biomedica, is one of the main manufacturers of the Astra Zeneca COVID vaccine and is also the company that helped Novartis get the cost of treatment for kids with leukaemia down from $3 million a go to $300,000. The company has gone from £20m value to over a billion (and in the FTSE250) in the last 7 years as a result.

The book explains what biotech is, what is coming next, and in a final section, how interested investors can profit from it.

on